Christabel N. Hikaambo-Mwila
- Country of Origin: Zambia
- Home University: University of Zambia
- Host University & Country: University of Cape Town - South Africa
- PhD Title: Repositioning the anticancer agent sapanisertib (MLN0128) as an inhibitor of Plasmodium phosphatidylinositol 4-kinase (PI4K) via a targeted covalent inhibitor approach
- Year of Completion: 2026
PhD Overview
While progress has been made in the fight against the devastating infectious disease of malaria, the emergence of drug-resistant malaria parasites threatens to undermine the gains achieved so far. My study involves using the targeted covalent inhibitor (TCI) approach to identify compounds that are active against Plasmodium phosphatidylinositol 4-kinase (PI4K), a clinically validated antimalarial drug target that is essential for malaria parasite survival across multiple life-cycle stages. This study aims to reposition the anticancer compound MLN0128 for the treatment of malaria by identifying and optimizing derivatives that covalently bind to Plasmodium PI4K.
Sustainability Goals
- Good Health and Well-being
- Industry, Innovation and Infrastructure
About Me
I am a trained pharmacist and an early career scientist with expertise in pharmaceutical sciences and medicinal chemistry. I am passionate about drug discovery and aim to continue with drug discovery research for neglected tropical diseases after completing my PhD.